πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9120851

Human antibodies to human angiopoietin-like protein 4

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9089599

Low affinity FCGR deficient mice

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9079948

Human antibodies to Fel d1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9056130

Humanized Fc gamma R mice

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9043996

Genetically modified major histocompatibility complex animals

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9028819

Methods of alleviating itch by administering human antibodies to human protease-activated

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9018356

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9017670

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9005617

Antikine antibodies that bind to multiple CC chemokines

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8987420

High affinity human antibodies to human angiopoietin-2

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8980268

Methods for treating cancer by administering an anti-Ang-2 antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8968736

Human antibodies to GFRΞ±3 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8945559

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8927233

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8921316

Stable liquid VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889133

Methods of treating diabetes with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8871209

Compositions and methods for increasing muscle mass and muscle strength by specifically an

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8865430

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8847004

Humanized M-CSF mice

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8840894

Antibodies to human GDF8

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8840886

Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802107

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8795669

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8791244

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted